📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Max Healthcare Reports 38% EBITDA CAGR and ₹1.02 Lakh Cr Market Cap in Investor Update
Max Healthcare showcased its position as India's largest hospital chain by market cap (₹1.02 lakh crore) with a strong 4-year EBITDA CAGR of 38% and Revenue CAGR of 24%. The company currently operates over 5,200 beds across 20 facilities, maintaining a high occupancy rate of 76% and a robust ROCE of 26% for 9M FY26. Growth is being driven by aggressive inorganic expansion, including recent acquisitions in Lucknow, Nagpur, and Noida, alongside significant brownfield expansions in Mumbai and Mohali.
Key Highlights
Achieved a 38% EBITDA CAGR and 24% Revenue CAGR over the last 4 years (FY21-FY25)
Current capacity exceeds 5,200 beds with 73% located in high-demand metro areas
Maintained a strong Return on Capital Employed (ROCE) of approximately 26% for 9M FY26
Institutional investors (FIIs and DIIs) hold a combined stake of over 71% as of December 2025
Ongoing expansion includes a 160-bed tower in Mohali and a 268-bed tower at Nanavati-Max
💼 Action for Investors
Investors should focus on the company's ability to maintain high ROCE while aggressively scaling bed capacity through both greenfield and inorganic routes. The stock remains a core play in the premium healthcare segment, though monitoring the integration of newly acquired assets like Sahara and Jaypee hospitals is essential.
Max Healthcare Q3 Revenue Up 10% YoY to INR 2,608 Cr; EBITDA Margin at 26.1%
Max Healthcare reported a 10% YoY revenue growth to INR 2,608 crore for Q3 FY26, although operating EBITDA margins contracted to 26.1% from 27.3% YoY. Performance was impacted by transitory factors including a temporary disruption in cashless services with insurers and revised CGHS pricing for chemotherapy drugs. Despite these headwinds, occupancy remained healthy at 74% on an expanded bed base, and ARPOB grew 3% YoY to INR 77,900. The company continues its aggressive expansion with new beds commissioned in Mumbai and Mohali, and a board-approved 260-bed addition at Max Dwarka.
Key Highlights
Gross revenue increased 10% YoY to INR 2,608 crore, while operating EBITDA grew 4% to INR 648 crore.
Average Revenue Per Occupied Bed (ARPOB) reached INR 77,900, reflecting a 3% YoY growth.
International patient revenue grew 14% YoY, now accounting for 9% of total hospital revenue.
Brownfield expansion is on track with 116 beds commissioned across Nanavati and Mohali units in Q3.
Net debt-to-EBITDA remains conservative at less than 1x, with INR 281 crore free cash flow generated during the quarter.
💼 Action for Investors
Investors should focus on the ramp-up of newly commissioned beds and the restoration of insurance contracts which are expected to normalize margins in Q4. The stock remains a strong long-term play given the robust 4,000+ bed expansion pipeline through FY29.
Max Healthcare Reports 38% EBITDA CAGR; Market Cap Reaches ₹1.02 Lakh Crore
Max Healthcare Institute Limited (MAXHEALTH) released its latest investor presentation, highlighting its position as India's largest hospital chain by market capitalization at ₹1.02 lakh crore. The company demonstrated robust financial performance with a 4-year EBITDA CAGR of 38% and a revenue CAGR of 24%. Operational efficiency remains high with a 9M FY26 occupancy rate of approximately 76% and a Return on Capital Employed (ROCE) of 26%. The presentation outlines a massive expansion pipeline across Delhi NCR, Mumbai, Lucknow, and Pune to further scale its 5,200+ bed capacity.
Key Highlights
Market capitalization stands at ₹1.02 lakh crore ($11.3 billion) as of December 31, 2025.
Achieved a 38% EBITDA CAGR and 24% Revenue CAGR over the last 4 years.
Current capacity exceeds 5,200 beds across 20 facilities with 73% of beds located in metro cities.
Maintained strong operational metrics with ~76% occupancy and ~26% ROCE for 9M FY26.
Significant expansion pipeline includes a ~1,000-bed project in Gurugram and a ~450-bed hospital development in Pune.
💼 Action for Investors
Investors should note the company's industry-leading ROCE and consistent EBITDA growth as evidence of high operational efficiency. The aggressive expansion roadmap across high-demand metros provides a clear long-term growth runway for the stock.
Max Healthcare Q3 Revenue Up 10% to ₹2,608 Cr; PAT Grows 9% to ₹344 Cr
Max Healthcare reported a steady Q3 FY26 with gross revenue rising 10% YoY to ₹2,608 Cr, supported by a 7% growth in occupied bed days. Network Operating EBITDA grew 4% YoY to ₹648 Cr, though margins saw a slight compression to 26.1% due to pre-commissioning expenses and regulatory shifts. PAT increased 9% YoY to ₹344 Cr, even after accounting for ₹55 Cr in exceptional items related to labor codes and stamp duties. The company is actively expanding, having commissioned new beds in Mohali and Mumbai while announcing a new 450-bed project in Pune.
Key Highlights
Gross Revenue grew 10% YoY to ₹2,608 Cr; Network PAT increased 9% YoY to ₹344 Cr.
ARPOB improved to ₹77.9k from ₹75.9k YoY, while bed occupancy stood at 74%.
Successfully commissioned 53 beds in Mohali and 63 beds in Nanavati Max with healthy initial margins of 39% and 31% respectively.
Announced staggered acquisition of Yerawada Properties in Pune for a new ~450-bed hospital project.
Exceptional charges of ₹55 Cr impacted the bottom line, alongside temporary headwinds from CGHS tariff revisions and drug pricing guidelines.
💼 Action for Investors
Investors should monitor the ramp-up of newly commissioned brownfield beds which are already delivering accretive margins. The company's aggressive expansion into Pune and Delhi NCR reinforces its long-term growth trajectory in the premium healthcare segment.
Max Healthcare Q3 Revenue Grows 10% to ₹2,608 Cr; PAT Up 9% to ₹344 Cr
Max Healthcare reported a steady Q3 FY26 with a 10% YoY revenue growth to ₹2,608 Cr and a 9% rise in PAT to ₹344 Cr, despite ₹55 Cr in exceptional charges. Operating margins compressed slightly to 26.1% from 27.3% due to pre-commissioning expenses for new beds and regulatory impacts on institutional drug pricing. The company is aggressively expanding, with new brownfield beds already operational in Mohali and Nanavati showing strong initial margins. Operational metrics remain healthy with ARPOB increasing to ₹77.9k and bed occupancy at 74%.
Key Highlights
Gross Revenue grew 10% YoY to ₹2,608 Cr, while Network Operating EBITDA rose 4% YoY to ₹648 Cr.
PAT increased 9% YoY to ₹344 Cr after accounting for ₹55 Cr in exceptional items related to wage codes and stamp duty.
ARPOB (Average Revenue Per Occupied Bed) improved to ₹77.9k, while bed occupancy stood at 74%.
Newly commissioned beds in Mohali (53 beds) and Nanavati (63 beds) delivered healthy EBITDA margins of 39% and 31% respectively.
Announced a new 450-bed hospital project in Pune via the acquisition of Yerawada Properties Pvt. Ltd.
💼 Action for Investors
Investors should view the slight margin compression as temporary due to expansion costs, while focusing on the strong performance of newly commissioned beds. The company's aggressive capacity addition and entry into the Pune market provide a clear roadmap for long-term growth.
Max Healthcare Q3 PAT Rises 26% YoY to ₹301 Cr; Dwarka Hospital Expansion Approved
Max Healthcare Institute reported a steady performance for Q3 FY26 with consolidated revenue growing 10.7% YoY to ₹2,067.5 crore. Net profit (PAT) saw a robust 26% YoY increase to ₹300.9 crore, despite an exceptional charge of ₹48.2 crore during the quarter. The company is aggressively pursuing growth, evidenced by the board's approval to add ~260 beds to its Dwarka facility, nearly doubling its current 300-bed capacity. While sequential (QoQ) performance showed a slight dip in revenue and profit, the nine-month PAT growth of 45% YoY highlights strong operational momentum.
Key Highlights
Consolidated Revenue from operations increased 10.7% YoY to ₹2,06,752 Lakhs.
Net Profit (PAT) for the quarter rose 26% YoY to ₹30,092 Lakhs from ₹23,880 Lakhs.
Board approved expansion of Max Super Speciality Hospital, Dwarka by adding ~260 additional beds.
Nine-month (9M FY26) PAT reached ₹1,10,019 Lakhs, a 45% increase over the previous year's ₹75,688 Lakhs.
Exceptional item of ₹4,824 Lakhs recorded in Q3 FY26, impacting the pre-tax profit.
💼 Action for Investors
Investors should remain positive on the stock given the strong YoY earnings growth and the clear roadmap for capacity expansion in high-demand areas like Dwarka. The long-term outlook remains healthy as the company scales its bed capacity and maintains double-digit revenue growth.
Max Healthcare to Invest INR 1000 Cr+ for New 450-Bed Hospital in Pune
Max Healthcare has announced its entry into the Pune market through the staggered acquisition of 100% equity in Yerawada Properties Private Limited. The company plans to develop a 450-bed super-specialty hospital with a total investment exceeding INR 1,000 crore. Located in the prime Yerawada area, the facility is expected to be commissioned within the next three years. This strategic move marks the company's fourth facility in Western India and aligns with its vision to capture high-growth urban healthcare markets.
Key Highlights
Total investment of over INR 1,000 crore for a 450-bed super-specialty hospital in Pune
Staggered acquisition of 100% equity stake in Yerawada Properties Private Limited (YPPL)
Facility expected to be commissioned over the next 3 years in the prime Yerawada locality
Marks the company's 4th facility in Western India, strengthening its Maharashtra presence
💼 Action for Investors
Investors should monitor the project's execution timeline and capital allocation efficiency over the next three years. The expansion into a high-demand urban market like Pune is a strong long-term growth driver for the company's portfolio.
Max Healthcare to Invest ₹1,020 Cr for New 450-Bed Hospital in Pune via YPPL Acquisition
Max Healthcare has approved the acquisition of a 100% equity stake in Yerawada Properties Private Limited (YPPL) to establish a new ~450-bed super speciality hospital in Pune. The total investment for this project is estimated at ₹1,020 crore, which includes the ₹200 crore acquisition cost, construction, and equipment. This strategic move aims to expand the company's footprint in Maharashtra, addressing high demand as its current network operates at over 76% capacity utilization. The project will be funded through a mix of internal accruals and debt, with a completion timeline of approximately four years.
Key Highlights
Acquisition of 100% equity in YPPL for ~₹200 crore to secure 1.68 acres of prime land in Pune.
Total capital expenditure of ₹1,020 crore planned for a new ~450-bed super speciality hospital.
Project completion and capacity addition expected over a period of approximately 4 years.
Strategic entry into the Pune market to leverage high existing network utilization of >76%.
Funding to be sourced through a combination of internal accruals and term loans.
💼 Action for Investors
This expansion is a strong long-term growth catalyst that diversifies Max Healthcare's geographic presence into the high-demand Pune market. Investors should view this as a positive development for future revenue scaling, though the four-year gestation period requires a long-term investment horizon.
Max Healthcare to Invest ₹1,020 Cr for New 450-Bed Hospital in Pune via YPPL Acquisition
Max Healthcare has approved the acquisition of Yerawada Properties Private Limited (YPPL) to facilitate the development of a new ~450-bed super speciality hospital in Pune. The total project investment is estimated at ₹1,020 Crore, which includes ~₹200 Crore for the 100% equity acquisition of YPPL and the remaining for construction and equipment. This move is aimed at addressing high capacity utilization across the existing network, which exceeded 76% in H1 FY26. The project will be funded through a mix of internal accruals and debt, with a completion timeline of approximately 4 years.
Key Highlights
Total investment of ₹1,020 Crore for a new ~450-bed super speciality hospital in Pune.
Acquisition of 100% equity in Yerawada Properties (YPPL) for ~₹200 Crore to secure 1.68 acres of land.
Project to be completed in a phased manner over an indicative timeline of 4 years.
Existing network capacity utilization is high at >76% as of H1 FY26, necessitating expansion.
Funding strategy involves a combination of internal accruals and term loans.
💼 Action for Investors
Investors should view this as a significant long-term growth catalyst that strengthens Max Healthcare's presence in the high-demand Maharashtra market. Monitor the company's debt-to-equity ratio as it takes on term loans for this large-scale capital expenditure.